

Tozinameran

S

Status migrainosus: case report

A 37-year-old woman developed status migrainosus (SMg) following administration of tozinameran for COVID-19 vaccination [duration of treatment to reaction onset not stated].

The woman was referred to a centre in Italy for persisting fluctuating moderate (VAS 5/10) to severe (VAS 8/10) right pulsating headache, which was associated with nausea, phonophobia and photophobia, which started 4 days before the presentation. She reported non-steroidal anti-inflammatory drugs (NSAIDs). She was unable either to perform her normal daily activities or work due to debilitating condition. She specifically started experiencing symptoms after second dose of tozinameran [Comirnaty; manufactured by Pfizer/BioNtech; route and dosage not stated]. Her past medical history was relevant for migraine without aura, which was occasionally managed with ibuprofen. Her current headache had same localisation as her usual headache; however, it was worse in severity and intensity. Subsequent brain MRI performed 3 days after the symptoms onset, demonstrated a large (maximum diameter 14mm), rounded cystic degeneration, involving the epiphysis. Based on ICHD-3 beta diagnostic criteria, a diagnosis of SMg was made. The occurrence of SMg was likely triggered by her recent COVID-19 vaccination.

The woman received ibuprofen for treatment and showed a little improvement of her condition. At day 11, she achieved complete recovery of headache associated with SMg.